請輸入關鍵字:

熱門搜尋:

Arthur D. Little Report Explores Impact of “Ultra-targeted” Healthcare

日期: 2019年5月7日 下午4:15

All segments of healthcare will need to adapt to unprecedented change driven by technological advancements in areas such as molecular biology, AI and digitalization

BOSTON--(BUSINESS WIRE)-- As pivotal changes in healthcare and drug development gain traction, new analysis from Arthur D. Little (ADL) highlights that all sectors of the industry must evolve their business and operating models in the coming decade.

From genomic treatments to Artificial Intelligence in diagnostics to leaps in curative medicine, the healthcare ecosystem is facing unprecedented change. ADL’s forward-looking assessment is captured in a new Report, “Future Health: How the industry will move from ‘one size fits all’ to ultra-targeted care.”

Several critical shifts are pushing major players across the world to adapt:

  • Targeted treatments are changing the way drugs are brought to market, with greater emphasis on patients’ biological make-ups. Already, 22% of drugs currently in development specify a biomarker as criteria for inclusion, according to ADL research.
  • ADL projects the global consumer genetic testing market will reach $50B by 2026, leading to an abundance of genomic data that will be available to guide prevention, diagnosis, and treatment.
  • Certain chronic diseases will become more curable or treatable, and patients with access to more data will have greater opportunity to prevent or manage their conditions.
  • Long-term care will continue to shift away from hospitals, which will in turn move their model from surgeries and long-term chronic care to a physician-led approach to curative therapies, and may lead them to consider onsite device and drug manufacturing.

Craig Wylie, Managing Partner at ADL in the United States, notes: “Incredible advances in genomics and diagnostics are leading to a future that will impact the entire breadth of the healthcare industry. Companies are in the early stages of evolving their approach to clinical trials, commercial models, and care provision.”

“The pace of change and the associated costs will be staggering,” continued Wylie. “The most successful organizations across all segments of the healthcare ecosystem will be those that adapt their business models, rethink their operations, and place an emphasis on collaboration and partnerships.”

To download the Report, please visit: www.adl.com/FutureHealth

Contacts

Cate Bonthuys
Catalyst Comms
cate@catalystcomms.co.uk
Tel: +44 7746546773

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至 content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載APP 下載財華財經APP,把握投資先機
更多精彩内容,請點擊: 財華網(https://www.finet.hk/) 財華智庫網(https://www.finet.com.cn) 現代電視FINTV(http://www.fintv.hk)

視頻

快訊

04:16
知名美股跌幅榜前十,ZipRecruiter, Inc. Class A(ZIP.US)跌18.57%,邁威爾科技(MRVL.US)跌5.57%
04:16
知名美股漲幅榜前十,Robinhood Markets, Inc. Class A(HOOD.US)漲+13.70%,歐文斯伊利諾斯玻璃(OI.US)漲+12.54%
04:15
中概股跌幅榜前十,NFT Limited Class A(MI.US)跌58.51%,榮誌集團(SUGP.US)跌42.34%
04:15
中概股漲幅榜前十,第九城市(NCTY.US)漲+32.57%,燦谷(CANG.US)漲+32.10%
04:15
美股跌幅榜前十,榮誌集團(SUGP.US)跌42.34%,GD Culture Group Limited(GDC.US)跌37.35%
04:15
美股漲幅榜前十,RF Acquisition Corp II(RFAI.US)漲+392.54%,RF Acquisition Corp II Unit Cons of 1 Shs + 1 Rt(RFAIU.US)漲+366.00%
21:46
知名美股跌幅榜前十,ZipRecruiter, Inc. Class A(ZIP.US)跌6.96%,厄比奎蒂(UI.US)跌8.16%
21:46
知名美股漲幅榜前十,Robinhood Markets, Inc. Class A(HOOD.US)漲+11.93%,Coinbase Global, Inc. Class A(COIN.US)漲+8.76%
21:45
中概股跌幅榜前十,見知教育(JZ.US)跌25.60%,羅科仕(LGCL.US)跌16.27%
21:45
中概股漲幅榜前十,榮誌集團(SUGP.US)漲+40.36%,嘉楠科技(CAN.US)漲+19.07%